Loading...
Atypical diffuse bilateral cystic lung changes secondary to erlotinib treatment in a patient with metastatic non-small cell lung carcinoma: A case report and literature review
Erlotinib is a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations. The response rate to erlotinib is ~...
Na minha lista:
| Udgivet i: | Mol Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
D.A. Spandidos
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6030992/ https://ncbi.nlm.nih.gov/pubmed/29977544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2018.1620 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|